Top

Current HIV/AIDS Reports

Published in:

Open Access 16-09-2022 | HIV Drug | The Science of Prevention (R Heffron and K Ngure, Section Editors)

Long-Acting Injectable Cabotegravir for HIV Prevention: What Do We Know and Need to Know about the Risks and Consequences of Cabotegravir Resistance?

Authors: Urvi M. Parikh, Catherine A. Koss, John W. Mellors

Published in: Current HIV/AIDS Reports | Issue 5/2022

Abstract

Purpose of Review

Cabotegravir is a potent integrase strand transfer inhibitor (INSTI) recently approved as a long-acting injectable formulation for HIV prevention (CAB-LA). We summarize what is known about cabotegravir pharmacokinetics, activity, and emergence of resistance from in vitro, macaque and clinical studies, and we evaluate the risk of resistance from CAB-LA with on-time injections and after CAB-LA discontinuation.

Recent Findings

The accumulation of multiple INSTI mutations is required for high-level cabotegravir resistance, and the same mutation combinations may cause cross-resistance to dolutegravir, which is widely used for first-line antiretroviral therapy in low- and middle-income countries. Though CAB-LA was highly effective in preventing HIV, breakthrough infections did occur in trials of CAB-LA despite on-time injections, resulting in selection of single and combinations of INSTI resistance mutations.

Summary

As CAB-LA is scaled-up, prompt HIV diagnosis to prevent resistance, and resistance monitoring could help preserve the effectiveness of INSTIs for both HIV treatment and prevention.

Fauci AS, Redfield RR, Sigounas G, Weahkee MD, Giroir BP. Ending the HIV Epidemic: A Plan for the United States. JAMA. 2019;321(9):844–5. https://doi.org/10.1001/jama.2019.1343.CrossRefPubMed

The Joint United Nations Programme on HIV/AIDS (UNAIDS). UNAIDS Data 2021. [JC3032E] Published: 29 November 2021. https://www.unaids.org/sites/default/files/media_asset/JC3032_AIDS_Data_book_2021_En.pdf [Accessed 01 June 2022]

Roehr B. FDA approves first drug to prevent HIV infection. BMJ. 2012;345: e4879. https://doi.org/10.1136/bmj.e4879.CrossRefPubMed

Baeten JM, Donnell D, Ndase P, Mugo NR, Campbell JD, Wangisi J, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med. 2012;367(5):399–410. https://doi.org/10.1056/nejmoa1108524.CrossRefPubMedPubMedCentral

Baeten JM, Heffron R, Kidoguchi L, Mugo NR, Katabira E, Bukusi EA, et al. Integrated delivery of antiretroviral treatment and pre-exposure prophylaxis to HIV-1-serodiscordant couples: a prospective implementation study in Kenya and Uganda. PLoS Med. 2016;13(8): e1002099. https://doi.org/10.1371/journal.pmed.1002099.CrossRefPubMedPubMedCentral

Grant RM, Anderson PL, McMahan V, Liu A, Amico KR, Mehrotra M, et al. Uptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: a cohort study. Lancet Infect Dis. 2014;14(9):820–9. https://doi.org/10.1016/s1473-3099(14)70847-3.CrossRefPubMedPubMedCentral

Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, Vargas L, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010;363(27):2587–99. https://doi.org/10.1056/nejmoa1011205.CrossRefPubMedPubMedCentral

Thigpen MC, Kebaabetswe PM, Paxton LA, Smith DK, Rose CE, Segolodi TM, et al. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med. 2012;367(5):423–34. https://doi.org/10.1056/nejmoa1110711.CrossRefPubMed

World Health Organization (WHO). Global data shows increasing PrEP use and widespread adoption of WHO PrEP recommendations: global PrEP network highlight - March 2021: World Health Organization; 2021 Published: 16 March 2021. Available from: https://www.who.int/news-room/feature-stories/detail/global-data-shows-increasing-prep-use-and-widespread-adoption-of-who-prep-recommendations. [Accessed 14 June 2022]

10.

Mayer KH, Molina JM, Thompson MA, Anderson PL, Mounzer KC, De Wet JJ, et al. Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial. Lancet. 2020;396(10246):239–54. https://doi.org/10.1016/s0140-6736(20)31065-5.CrossRefPubMed

11.

World Health Organization (WHO). Guidelines: updated recommendations on HIV prevention, infant diagnosis, antiretroviral initiation and monitoring. Published March 2021. 2021 https://apps.who.int/iris/bitstream/handle/10665/341052/9789240023581-eng.pdf?sequence=1&isAllowed=y [Accessed 01 June 2022].

12.

Baeten JM, Palanee-Phillips T, Brown ER, Schwartz K, Soto-Torres LE, Govender V, et al. Use of a vaginal ring containing dapivirine for HIV-1 prevention in women. N Engl J Med. 2016. https://doi.org/10.1056/nejmoa1506110.CrossRefPubMedPubMedCentral

13.

Baeten JM, Palanee-Phillips T, Mgodi NM, Mayo AJ, Szydlo DW, Ramjee G, et al. Safety, uptake, and use of a dapivirine vaginal ring for HIV-1 prevention in African women (HOPE): an open-label, extension study. Lancet HIV. 2021;8(2):e87–95. https://doi.org/10.1016/s2352-3018(20)30304-0.CrossRefPubMedPubMedCentral

14.

Nel A, van Niekerk N, Kapiga S, Bekker LG, Gama C, Gill K, et al. Safety and efficacy of a dapivirine vaginal ring for HIV prevention in women. N Engl J Med. 2016;375(22):2133–43. https://doi.org/10.1056/nejmoa1602046.

15.

Nel A, van Niekerk N, Van Baelen B, Malherbe M, Mans W, Carter A, et al. Safety, adherence, and HIV-1 seroconversion among women using the dapivirine vaginal ring (DREAM): an open-label, extension study. Lancet HIV. 2021;8(2):e77–86. https://doi.org/10.1016/s2352-3018(20)30300-3.CrossRefPubMed

16.

Bekker LG, Pike C, Hillier SL. HIV prevention: better choice for better coverage. J Int AIDS Soc. 2022;25(1): e25872. https://doi.org/10.1002/jia2.25872.CrossRefPubMedPubMedCentral

17.

•• Landovitz RJ, Donnell D, Clement ME, Hanscom B, Cottle L, Coelho L, et al. Cabotegravir for HIV prevention in cisgender men and transgender women. N Engl J Med. 2021;385(7):595–608. https://doi.org/10.1056/nejmoa2101016. This pivotal paper showed superiority of CAB-LA to daily oral TDF/FTC in preventing HIV infection among 4566 trangender women and men who have sex with men (MSM) in the HPTN 083 trial. The paper also describes INSTI resistance identified in the individuals who seroconverted in the trial.

18.

•• Marzinke MA, Grinsztejn B, Fogel JM, Piwowar-Manning E, Li M, Weng L, et al. Characterization of HIV infection in cisgender men and transgender women who have sex with men receiving injectable cabotegravir for HIV prevention: HPTN 083. J Infect Dis. 2021. https://doi.org/10.1093/infdis/jiab152. A detailed evaluation of the 58 infections that occurred in the HPTN 083 study are presented, including data on delayed HIV diagnosis, emergence of drug resistance, and initiation of antiretroviral therapy.

19.

•• Delany-Moretlwe S, Hughes JP, Bock P, Ouma SG, Hunidzarira P, Kalonji D, et al. Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial. Lancet. 2022;399(10337):1779-89.https://doi.org/10.1016/s0140-6736(22)00538-4 .The HPTN 084 randomised, double-blind, active-controlled, superiority trial in 3224 reproductive aged women in seven countries in sub-Saharan Africa showed superiority of CAB-LA in preventing HIV infection compared to TDF/FTC.

20.

•• Eshleman SH, Fogel JM, Piwowar-Manning E, Chau G, Cummings V, Agyei Y, et al. Characterization of human immunodeficiency virus (HIV) infections in women who received injectable Cabotegravir or Tenofovir Disoproxil Fumarate/Emtricitabine for HIV Prevention: HPTN 084. J Infect Dis. 2022.https://doi.org/10.1093/infdis/jiab576. In depth data on the 40 infections identified in the HPTN 084 study comparing CAB-LA to TDF/FTC in women are detailed in this paper.

21.

Donnell D, Gao F, Hughes J, Hanscom B, Corey L, Cohen MS, et al. Counterfactual estimation of CAB-LA efficacy against placebo using external trials. Abstract 86. Oral-07. Conference on Retroviruses and Opportunistic Infections; 2022; Virtual. 2022 Feb 12–16.

22.

World Health Organization (WHO). Guidelines on long-acting injectable cabotegravir for HIV prevention. Published July 2022. Available from: https://www.who.int/publications/i/item/9789240054097. Accessed 24 Aug 2022.

23.

•• Landovitz RJ, Li S, Eron JJ, Jr., Grinsztejn B, Dawood H, Liu AY, et al. Tail-phase safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in HIV-uninfected adults: a secondary analysis of the HPTN 077 trial. Lancet HIV. 2020;7(7):e472-e81. https://doi.org/10.1016/s2352-3018(20)30106-5. Participants at low risk for HIV infection were randomly assigned to CAB-LA at different doses to estimate the time to lower limit of quantitation of CAB between the last injection and up to 76 weeks post-final injection. Cabotegravir could be detected at a median of 43 weeks for men and 67 weeks for women, with longer cabotegravir exposure in individuals with higher body-mass indices.

24.

World Health Organization. HIV drug resistance report 2021. Geneva: World Health Organization; 2021. Licence: CC BY-NC-SA 3.0 IGO. https://www.who.int/publications/i/item/9789240038608. 2021. Contract No.: ISBN 978–92–4–003860–8.

25.

Johns BA, Kawasuji T, Weatherhead JG, Taishi T, Temelkoff DP, Yoshida H, et al. Carbamoyl pyridone HIV-1 integrase inhibitors 3. A diastereomeric approach to chiral nonracemic tricyclic ring systems and the discovery of dolutegravir (S/GSK1349572) and (S/GSK1265744). J Med Chem. 2013;56(14):5901–16. https://doi.org/10.1021/jm400645w

26.

Smith SJ, Zhao XZ, Burke TR Jr, Hughes SH. Efficacies of Cabotegravir and Bictegravir against drug-resistant HIV-1 integrase mutants. Retrovirology. 2018;15(1):37. https://doi.org/10.1186/s12977-018-0420-7.CrossRefPubMedPubMedCentral

27.

Yoshinaga T, Kobayashi M, Seki T, Miki S, Wakasa-Morimoto C, Suyama-Kagitani A, et al. Antiviral characteristics of GSK1265744, an HIV integrase inhibitor dosed orally or by long-acting injection. Antimicrob Agents Chemother. 2015;59(1):397–406. https://doi.org/10.1128/aac.03909-14.CrossRefPubMed

28.

Yoshinaga T, Seki T, Miki S, Miyamoto T, Suyama-Kagitani A, Kawauchi-Miki S, et al. Novel secondary mutations C56S and G149A confer resistance to HIV-1 integrase strand transfer inhibitors. Antiviral Res. 2018;152:1–9. https://doi.org/10.1016/j.antiviral.2018.01.013.CrossRefPubMed

29.

• Smith SJ, Zhao XZ, Passos DO, Lyumkis D, Burke TR, Jr., Hughes SH. HIV-1 Integrase Inhibitors That Are Active against Drug-Resistant Integrase Mutants. Antimicrob Agents Chemother. 2020;64(9). https://doi.org/10.1128/aac.00611-20. A panel of INSTI resistance mutants was developed and tested against current and novel integrase inhibitors to better understand the resistance profile of INSTIs.

30.

• Martin C, Gracias S, Charpentier C, Descamps D, Le Hingrat Q, Plantier JC, et al. HIV-1 non-group M phenotypic susceptibility in vitro to bictegravir and cabotegravir. J Antimicrob Chemother. 2021;76(9):2306-9.https://doi.org/10.1093/jac/dkab196. A large panel of clinical isolates of varying subtypes were evaluated for phenotypic susceptibility to cabotegravir to evaluate the effect of naturally occurring polymorphisms on cabotegravir activity.

31.

Zhang WW, Cheung PK, Oliveira N, Robbins MA, Harrigan PR, Shahid A. Accumulation of multiple mutations in vivo confers cross-resistance to new and existing integrase inhibitors. J Infect Dis. 2018;218(11):1773–6. https://doi.org/10.1093/infdis/jiy428.CrossRefPubMed

32.

Saladini F, Giannini A, Boccuto A, Dragoni F, Appendino A, Albanesi E, et al. Comparable in vitro activities of second-generation HIV-1 integrase strand transfer inhibitors (INSTIs) on HIV-1 Clinical Isolates with INSTI Resistance Mutations. Antimicrob Agents Chemother. 2019;64(1). https://doi.org/10.1128/aac.01717-19

33.

Oliveira M, Ibanescu RI, Anstett K, Mesplede T, Routy JP, Robbins MA, et al. Selective resistance profiles emerging in patient-derived clinical isolates with cabotegravir, bictegravir, dolutegravir, and elvitegravir. Retrovirology. 2018;15(1):56. https://doi.org/10.1186/s12977-018-0440-3.CrossRefPubMedPubMedCentral

34.

Neogi U, Singh K, Aralaguppe SG, Rogers LC, Njenda DT, Sarafianos SG, et al. Ex-vivo antiretroviral potency of newer integrase strand transfer inhibitors cabotegravir and bictegravir in HIV type 1 non-B subtypes. AIDS. 2018;32(4):469–76. https://doi.org/10.1097/qad.0000000000001726.CrossRefPubMed

35.

• Cheung PK, Shahid A, Dong W, Lepik KJ, Montaner JSG, Brockman MA, et al. Impact of combinations of clinically observed HIV integrase mutations on phenotypic resistance to integrase strand transfer inhibitors (INSTIs): a molecular study. J Antimicrob Chemother. 2022;77(4):979–88. https://doi.org/10.1093/jac/dkab498. A comprehensive series of recombinant NL4.3 viral constructs with different combinations of integrase seqeunce mutations was created and phenotyped to identify the key mutations that confer high-level resitance to INSTIs including cabotegravir.

36.

Wensing AM, Calvez V, Ceccherini-Silberstein F, Charpentier C, Gunthard HF, Paredes R, et al. 2019 update of the drug resistance mutations in HIV-1. Top Antivir Med. 2019;27(3):111–21.PubMedPubMedCentral

37.

Rhee SY, Gonzales MJ, Kantor R, Betts BJ, Ravela J, Shafer RW. Human immunodeficiency virus reverse transcriptase and protease sequence database. Nucleic Acids Res. 2003;31(1):298–303. https://doi.org/10.1093/nar/gkg100.CrossRefPubMedPubMedCentral

38.

Shafer RW. Rationale and uses of a public HIV drug-resistance database. J Infect Dis. 2006;194(Suppl 1):S51–8. https://doi.org/10.1086/505356.CrossRefPubMed

39.

Andrews CD, Spreen WR, Mohri H, Moss L, Ford S, Gettie A, et al. Long-acting integrase inhibitor protects macaques from intrarectal simian/human immunodeficiency virus. Science. 2014;343(6175):1151–4. https://doi.org/10.1126/science.1248707.CrossRefPubMedPubMedCentral

40.

• Radzio-Basu J, Council O, Cong ME, Ruone S, Newton A, Wei X, et al. Drug resistance emergence in macaques administered cabotegravir long-acting for pre-exposure prophylaxis during acute SHIV infection. Nature communications. 2019;10(1):2005. https://doi.org/10.1038/s41467-019-10047-w. The emergence of INSTI resistance mutations was demonstrated in macaque studies modeling the risk of receiving CAB-LA in the interval between infection and seroconversion.

41.

Orkin C, Arasteh K, Gorgolas Hernandez-Mora M, Pokrovsky V, Overton ET, Girard PM, et al. Long-Acting Cabotegravir and Rilpivirine after Oral Induction for HIV-1 Infection. N Engl J Med. 2020;382(12):1124–35. https://doi.org/10.1056/nejmoa1909512.CrossRefPubMed

42.

• Orkin C, Oka S, Philibert P, Brinson C, Bassa A, Gusev D, et al. Long-acting cabotegravir plus rilpivirine for treatment in adults with HIV-1 infection: 96-week results of the randomised, open-label, phase 3 FLAIR study. Lancet HIV. 2021;8(4):e185-e96.https://doi.org/10.1016/s2352-3018(20)30340-4. The 96-week results of the FLAIR trial for cabotegravir/rilpivirine treatment are presented in this study.

43.

Margolis DA, Gonzalez-Garcia J, Stellbrink HJ, Eron JJ, Yazdanpanah Y, Podzamczer D, et al. Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial. Lancet. 2017;390(10101):1499–510. https://doi.org/10.1016/s0140-6736(17)31917-7.CrossRefPubMed

44.

• Overton ET, Richmond G, Rizzardini G, Jaeger H, Orrell C, Nagimova F, et al. Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study. Lancet. 2021;396(10267):1994–2005. https://doi.org/10.1016/s0140-6736(20)32666-0. The 48-week results of the ATLAS-2M trial for cabotegravir/rilpivirine treatment in treatment experienced HIV-1 infected adults in 13 countries demonstrated the efficacy and safety of using cabotegravir and rilpivirine therapeutically with dosing every 2 months.

45.

• Jeffrey JL, St Clair M, Wang P, Wang C, Li Z, Beloor J, et al. Impact of integrase sequences from HIV-1 subtypes A6/A1 on the in vitro potency of Cabotegravir or Rilpivirine. Antimicrob Agents Chemother. 2022;66(3):e0170221. https://doi.org/10.1128/aac.01702-21. The integrase polymorphism L74I was not found to impact cabotegravir susceptibility in vitro in HIV-1 subtype B and A6.

46.

Hu ZX, Cordwell T, Jeffrey JL, Kuritzkes DR. Effect of L74I Polymorphisms on fitness of HIV-1 subtype A6 resistant to Cabotegravir. Poster 506. Conference on Retroviruses and Opportunistic Infections; February 12–16, 2022; Virtual; February 12–16, 2022.

47.

Clement ME, Kofron R, Landovitz RJ. Long-acting injectable cabotegravir for the prevention of HIV infection. Curr Opin HIV AIDS. 2020;15(1):19–26. https://doi.org/10.1097/coh.0000000000000597.CrossRefPubMedPubMedCentral

48.

Markowitz M, Frank I, Grant RM, Mayer KH, Elion R, Goldstein D, et al. Safety and tolerability of long-acting cabotegravir injections in HIV-uninfected men (ECLAIR): a multicentre, double-blind, randomised, placebo-controlled, phase 2a trial. Lancet HIV. 2017;4(8):e331–40. https://doi.org/10.1016/s2352-3018(17)30068-1.CrossRefPubMed

49.

Eshleman S, Fogel JM, Halvas EK, Mellors JW, Piwowar-Manning EM, Rinehart AR, et al. CAB-LA PrEP: early detection of HIV infection may reduce InSTI resistance risk. Abstract 95. Conference on Retroviruses and Opportunistic Infections; Virtual, February 12–16, 2022.

50.

Joint United Nations Programme on HIV/AIDS (UNAIDS). Global AIDS Update 2021. Confronting inequalities: lessons for pandemic responses from 40 Years of AIDS. [JC3020E] Available from: https://www.unaids.org/sites/default/files/media_asset/2021-global-aids-update_en.pdf; Accessed 14 June 2022.

51.

Thomson KA, Hughes J, Baeten JM, John-Stewart G, Celum C, Cohen CR, et al. Increased risk of HIV acquisition among women throughout pregnancy and during the postpartum period: a prospective per-coital-act analysis among women with HIV-infected partners. J Infect Dis. 2018;218(1):16–25. https://doi.org/10.1093/infdis/jiy113.CrossRefPubMedPubMedCentral

52.

United States Department of Health and Human Services Panel on Treatment of HIV During Pregnancy and Prevention of Perinatal Transmission. Recommendations for the Use of Antiretroviral Drugs During Pregnancy and Interventions to Reduce Perinatal HIV Transmission in the United States. https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/Perinatal_GL.pdf. Accessed 14 April 2022; 2022.

53.

Patel P, Ford SL, Baker M, Meyer C, Garside L, D'Amico R, et al. Pregnancy outcomes and pharmacokinetics in pregnant women living with HIV exposed to long-acting Cabotegravir and Rilpivirine in clinical trials. Abstract 885. ID Week; Virtual. 29 Sep - 03 Oct 2021.

54.

Delany-Moretlwe S, Hughes J, Guo X, Hanscom B, Hendrix CW, Farrior J, et al. Evaluation of CAB-LA safety and PK in pregnant women in the blinded phase of HPTN 084. Abstract 700. Conference on Retroviruses and Opportunistic Infections; Virtual. February 12–16, 2022.

55.

Trezza C, Ford SL, Gould E, Lou Y, Huang C, Ritter JM, et al. Lack of effect of oral cabotegravir on the pharmacokinetics of a levonorgestrel/ethinyl oestradiol-containing oral contraceptive in healthy adult women. Br J Clin Pharmacol. 2017;83(7):1499–505. https://doi.org/10.1111/bcp.13236.CrossRefPubMedPubMedCentral

56.

• Blair CS, Li S, Chau G, Cottle L, Richardson P, Marzinke MA, et al. Brief report: hormonal contraception use and cabotegravir pharmacokinetics in HIV-uninfected women enrolled in HPTN 077. J Acquir Immune Defic Syndr. 2020;85(1):93-7.https://doi.org/10.1097/qai.0000000000002409. The impact of hormonal contraceptives using pharmakokinetic parameters are evaluated in a secondary analysis of a Phase 2a study of cisgender women (HPTN 077) given oral cabotegravir followed by different doses of a CAB-LA injection.

57.

Stutterheim SE, van Dijk M, Wang H, Jonas KJ. The worldwide burden of HIV in transgender individuals: an updated systematic review and meta-analysis. PLoS ONE. 2021;16(12): e0260063. https://doi.org/10.1371/journal.pone.0260063.CrossRefPubMedPubMedCentral

58.

Blumenthal J, Goyal R, Burke L, Dubé M, Hoenigl M, Moore DJ, et al. The bidirectional effects of hormone therapy and PrEP in transgender individuals. Abstract 84. Conference on Retroviruses and Opportunistic Infections; Virtual. February 12–16, 2022.

59.

Sevelius JM, Glidden DV, Deutsch M, Welborn L, Contreras A, Salinas A, et al. Uptake, retention, and adherence to pre-exposure prophylaxis (PrEP) in TRIUMPH: a peer-led PrEP demonstration project for transgender communities in Oakland and Sacramento, California. J Acquir Immune Defic Syndr. 2021;88(S1):S27–38. https://doi.org/10.1097/qai.0000000000002808.

60.

Grinsztejn B, Hanscom B, Wang Z, Donnell D, Richardson P, Sullivan P, et al. Transgender women (TGW) in HPTN 083: an evaluation of safety, efficacy, and gender affirming hormonal therapy (GAHT) interactions with long-acting cabotegravir (CAB-LA). Abstract EPLBC04. AIDS 2022; Montreal, Canada; July 29-August 2, 2022.

61.

Paton NI, Musaazi J, Kityo C, Walimbwa S, Hoppe A, Balyegisawa A, et al. Dolutegravir or Darunavir in combination with Zidovudine or Tenofovir to treat HIV. N Engl J Med. 2021;385(4):330–41. https://doi.org/10.1056/nejmoa2101609.CrossRefPubMed

62.

Orkin C. New antiretrovirals and the future of HIV treatment and prevention. Abstract 116. Conference on Retroviruses and Opportunistic Infections; Virtual. February 12–16, 2022.

Title: Long-Acting Injectable Cabotegravir for HIV Prevention: What Do We Know and Need to Know about the Risks and Consequences of Cabotegravir Resistance?
Authors: Urvi M. Parikh
Catherine A. Koss
John W. Mellors
Publication date: 16-09-2022
Publisher: Springer US
Keywords: HIV Drug
Human Immunodeficiency Virus
Dolutegravir
Published in: Current HIV/AIDS Reports / Issue 5/2022
Print ISSN: 1548-3568
Electronic ISSN: 1548-3576
DOI: https://doi.org/10.1007/s11904-022-00616-y

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Long-Acting Injectable Cabotegravir for HIV Prevention: What Do We Know and Need to Know about the Risks and Consequences of Cabotegravir Resistance?

Abstract

Purpose of Review

Recent Findings

Summary

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Purpose of Review

Recent Findings

Summary

Please log in to get access to this content

Other articles of this Issue 5/2022

Ingestible Electronic Sensors for Monitoring Real-time Adherence to HIV Pre-exposure Prophylaxis and Antiretroviral Therapy

Bone Quality in Relation to HIV and Antiretroviral Drugs

Ectopic Fat and Cardiac Health in People with HIV: Serious as a Heart Attack

Using Behavioral Economics to Support PrEP Adherence for HIV Prevention

Measuring and Addressing Stigma Within HIV Interventions for People Who Use Drugs: a Scoping Review of Recent Research

Overcoming Vaccine Hesitancy for Future COVID-19 and HIV Vaccines: Lessons from Measles and HPV Vaccines

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page